Prioritization

Commercial Biomaterials Business, Degenerative Disease Programs Continue to Gather Momentum Animal and Preclinical Data Support Significant Opportunities in Osteoarthritis for…

Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization and Expense Reduction Advancing…

Image: FellowNeko/Adobe Stock Work management platform Asana has rolled out a new suite of features and product integrations designed to automatically give enterprise leaders a…

Company now focused on advancing lead clinical candidate mavorixafor in chronic neutropenic disorders, including WHIM syndrome Important mavorixafor clinical milestones anticipated in 2H…

– Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff…

Just a short time devoted to a mental or physical escape can work consistent wonders for mind, body and the bottom line. July 31, 2021…

- Company to focus on development of next-generation phage product candidates from ImmunoPhage platform and monoclonal antibody and nanobody programs - - Discontinuation of…